Compartilhar
Informação da revista
Vol. 43. Núm. S3.
Páginas S52 (Novembro 2021)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Vol. 43. Núm. S3.
Páginas S52 (Novembro 2021)
PP 53
Open Access
WHAT HAVE WE EXPERIENCED WITH COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISORDERS?
Visitas
1200
Simge ERDEM1, Metban MASTANZADE1, Mustafa Murat OZBALAK1, Sevda SERT EKINCI2, Dilek Ozden OZLUK1, Tarık Onur TIRYAKI1, Beyza OLUK1, Ipek YONAL HINDILERDEN1, Mustafa Nuri YENEREL1, Meliha NALCACI1, Tufan TUKEK2, Sevgi KALAYOGLU BESISIK1
1 Istanbul University Istanbul Faculty of Medicine, Internal Medicine Department/Hematology Division
2 Istanbul University Istanbul Faculty of Medicine, Internal Medicine Department
Este item recebeu

Under a Creative Commons license
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 43. Núm S3
Mais dados
Objective

Patients with cancer are considered highly vulnerable to the COVID-19 disease. However, there are still few data in hematologic patients. Some small studies have shown a high mortality on patients with hematologic malignancies and COVID-19. In this study we aim to report a single center experience of the hematologic patient population with COVID-19 disease.

Methodology

This single centre, retrospective, cohort study included a total of 111 adult patients (aged ≥18 years) with diagnosis of neoplastic and non-neoplastic hematologic diseases between March 2020 and August 2021. Ethics committee approval was obtained from the Istanbul University Istanbul Faculty of Medicine Clinical Research Ethics Committee. Categorical variables were compared using Pearson's Chi-square test. STATA16-MP was used for the statistical analysis.

Results

A total of 111 patients (median age:55) with hematologic disease were diagnosed with COVID19. Ninety patients had neoplastic hematologic disorder. Fourty-five patients were receiving anti-neoplastic treatment at the time of COVID19 diagnosis. A total of 21 patients (overall mortality rate:19%) died and 19 of them had neoplastic disorder. The malignancy mortality rate was estimated to be 21%. 45 of 90 cases were receiving chemotherapy. Ten of these 45 patients (22%) died due to COVID19 disease.

Conclusion

In our study the majority of patients who died due to COVID-19 had hematological malignancies. The cytokine storm which affects the clinical outcome in COVID-19 may contribute to dismal prognosis in hematologic malignancies in which cytokine increase is a part of process. Most of the succumbed patients were relapsed refractory multiple line treated which may reflect the immune insufficiency. It seemed COVID-19 progress is mostly poor in hematologic malignancies compared otherwise healthy people.

O texto completo está disponível em PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas